Microbe-Binding Agent Blocking for Sepsis Detection Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for sepsis are time-consuming and unreliable, often requiring 18-24 hours for microbiological analysis, leading to delayed treatment and high mortality rates due to the inability to rapidly and accurately detect infectious pathogens in patients, food, water, and environmental surfaces.
Innovation Solution
Pre-treating a target-binding agent, such as a microbe-binding agent with a mannan-binding domain, with an intermediate-affinity blocking agent like glucose to reduce non-target binding and enhance specificity and sensitivity for microbes, allowing for the differentiation between target and interfering agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional microbiological analysis methods are used to detect infectious pathogens, then detection reliability is maintained through comprehensive analysis, but detection time is excessively long (18-24 hours) leading to delayed treatment
Solution Approach 1:
The detection system is segmented into multiple functional components: target-binding agents with specific domains (mannan-binding, lipopolysaccharide-binding), blocking agents for reducing non-specific binding, and detection agents. This segmentation allows parallel processing of different detection functions, reducing overall detection time while maintaining reliability through multiple validation points
Solution Approach 2:
Blocking agents are pre-applied to target-binding agents before sample introduction to prevent non-specific binding of interfering agents. This preliminary action reduces background noise and false positives in advance, eliminating the need for lengthy post-detection validation steps and accelerating reliable detection
2Measurement precision
If target-binding agents are used to detect microbes in complex samples, then detection sensitivity is improved, but non-specific binding of interfering agents (such as haemocytes) causes false positives that reduce detection reliability
Solution Approach 1:
Blocking agents serve as intermediary molecules that temporarily occupy non-specific binding sites on target-binding agents. These intermediaries prevent interfering agents like haemocytes from binding non-specifically, while allowing specific target-microbe binding to occur. This mediation maintains detection sensitivity while eliminating false positives
Solution Approach 2:
Blocking agents are applied in advance to counteract the potential non-specific binding of interfering agents before they can cause false positives. This preliminary anti-action specifically addresses the harmful effect of non-specific binding without interfering with the desired specific binding between target-binding agents and microbial targets
3Measurement precision
If blocking agents are applied to reduce non-specific binding, then detection specificity is improved, but the complexity of the detection protocol increases
Solution Approach 1:
The blocking agent application is merged with the target-binding agent preparation step, creating a pre-formed complex that is then introduced to the sample. This consolidation of steps reduces the number of separate operations required, maintaining high detection specificity while simplifying the overall protocol
Solution Approach 2:
Blocking agents are designed with multi-functionality: they block non-specific binding sites, maintain target-binding agent stability, and do not interfere with specific target detection. This multi-functionality allows a single reagent to address multiple concerns, reducing the number of different components and steps needed in the protocol
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the binding specificity and sensitivity of the microbe-binding agent, reducing false positives and enabling faster and more accurate detection of infectious agents, thereby facilitating timely and appropriate treatment.
Implementation Method 1
pre-treating a target-binding agent, such as a microbe-binding agent with a mannan-binding domain, with an intermediate-affinity blocking agent like glucose to reduce non-target binding
Data Source
AI summary
Methods, compositions, kits and systems for detecting and/or capturing a target entity in a sample are disclosed. In particular, the methods, compositions and kits described herein can be used for pretreatment of target-binding agents with a blocking agent to reduce non-target binding in a complex matrix (e.g., blood). Methods and compositions for detecting and/or capturing a microbe in a test sample, including bodily fluids such as blood and tissues of a subject, food, water, and environmental surfaces are also disclosed.